News
Seanergy Maritime Holdings Corp (SHIP) Q2 Earnings and Revenues Surpass Estimates
Seanergy Maritime Holdings Corp (SHIP) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.77 per share a
Gear Up for Yelp (YELP) Q2 Earnings: Wall Street Estimates for Key Metrics
In its upcoming report, Yelp (YELP) is predicted by Wall Street analysts to post quarterly earnings of $0.48 per share, reflecting a decline of 11.1% compared to the same period last year
Countdown to Royalty Pharma (RPRX) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Analysts on Wall Street project that Royalty Pharma (RPRX) will announce quarterly earnings of $1.10 per share in its forthcoming report, representing an increase of 14.6% year over year. Revenues
Exploring Analyst Estimates for Wynn (WYNN) Q2 Earnings, Beyond Revenue and EPS
The upcoming report from Wynn Resorts (WYNN) is expected to reveal quarterly earnings of $1.20 per share, indicating an increase of 7.1% compared to the year-ago period. Analysts forecast revenues
Exploring Analyst Estimates for Zimmer (ZBH) Q2 Earnings, Beyond Revenue and EPS
In its upcoming report, Zimmer Biomet (ZBH) is predicted by Wall Street analysts to post quarterly earnings of $1.98 per share, reflecting a decline of 1.5% compared to the same period last year
Uniti Group (UNIT) Q2 FFO and Revenues Lag Estimates
Uniti Group (UNIT) came out with quarterly funds from operations (FFO) of $0.36 per share, missing the Zacks Consensus Estimate of $0.7 per share. This compares to FFO of $0.34 per share a year ago
Portillo's Inc. (PTLO) Meets Q2 Earnings Estimates
Portillo's Inc. (PTLO) came out with quarterly earnings of $0.12 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.1 per share a year ago. These figures are
Unlocking Q2 Potential of Plains All American (PAA): Exploring Wall Street Estimates for Key Metrics
Wall Street analysts expect Plains All American Pipeline (PAA) to post quarterly earnings of $0.30 per share in its upcoming report, which indicates a year-over-year decline of 3.2%. Revenues are
Somnigroup International (SGI) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
Wall Street analysts expect Somnigroup International (SGI) to post quarterly earnings of $0.51 per share in its upcoming report, which indicates a year-over-year decline of 19.1%. Revenues are
IPG Photonics (IPGP) Q2 Earnings and Revenues Surpass Estimates
IPG Photonics (IPGP) came out with quarterly earnings of $0.3 per share, beating the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.45 per share a year ago. These
Mesa Labs (MLAB) Lags Q1 Earnings and Revenue Estimates
Mesa Labs (MLAB) came out with quarterly earnings of $2.32 per share, missing the Zacks Consensus Estimate of $2.46 per share. This compares to earnings of $2.83 per share a year ago. These figures
Global Ship Lease (GSL) Beats Q2 Earnings and Revenue Estimates
Global Ship Lease (GSL) came out with quarterly earnings of $2.67 per share, beating the Zacks Consensus Estimate of $2.15 per share. This compares to earnings of $2.46 per share a year ago. These
Great Lakes Dredge & Dock (GLDD) Beats Q2 Earnings and Revenue Estimates
Great Lakes Dredge & Dock (GLDD) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $0.11 per share a year
Curious about Insulet (PODD) Q2 Performance? Explore Wall Street Estimates for Key Metrics
In its upcoming report, Insulet (PODD) is predicted by Wall Street analysts to post quarterly earnings of $0.93 per share, reflecting an increase of 69.1% compared to the same period last year
What Analyst Projections for Key Metrics Reveal About Texas Roadhouse (TXRH) Q2 Earnings
Analysts on Wall Street project that Texas Roadhouse (TXRH) will announce quarterly earnings of $1.95 per share in its forthcoming report, representing an increase of 8.9% year over year. Revenues
Insights Into BCE (BCE) Q2: Wall Street Projections for Key Metrics
Wall Street analysts forecast that BCE (BCE) will report quarterly earnings of $0.52 per share in its upcoming release, pointing to a year-over-year decline of 8.8%. It is anticipated that
Fox (FOXA) Beats Q4 Earnings and Revenue Estimates
Fox (FOXA) came out with quarterly earnings of $1.27 per share, beating the Zacks Consensus Estimate of $1.01 per share. This compares to earnings of $0.9 per share a year ago. These figures are
Illumina (ILMN) Reliance on International Sales: What Investors Need to Know
Have you evaluated the performance of Illumina's (ILMN) international operations for the quarter ending June 2025? Given the extensive global presence of this genetic testing tools company
Can These 6 Energy Stocks Surpass Q2 Earnings Estimates?
The oil/energy sector is under pressure in the second quarter of 2025, as falling crude oil prices and narrowing profit margins create a difficult operating environment. With roughly 25% of S&P 500
DuPont's Earnings & Sales Top Estimates in Q2 on Higher Volumes
DuPont de Nemours, Inc. DD registered second-quarter 2025 profit from continuing operations of $238 million or 54 cents per share. In the year-ago quarter, the company recorded a profit of $176
Curis (CRIS) Reports Q2 Loss, Beats Revenue Estimates
Curis (CRIS) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $1.99. This compares to a loss of $2.03 per share a year ago. These figures are
3 Top Dividend Stocks to Maximize Your Retirement Income
Here's an eye-opening statistic: older Americans are more afraid of running out of money than of death itself.
And unfortunately, even retirees who have built a nest egg have good reason to be
Core Molding Technologies (CMT) Q2 Earnings and Revenues Beat Estimates
Core Molding Technologies (CMT) came out with quarterly earnings of $0.47 per share, beating the Zacks Consensus Estimate of $0.46 per share. This compares to earnings of $0.73 per share a year ago
Cabometyx Sales Miss Mark in Q2: What Does This Mean for EXEL Stock?
Exelixis’ (EXEL) lead drug, Cabometyx, a tyrosine kinase inhibitor (TKI), maintains a dominant position for the treatment of renal cell carcinoma (RCC) in both the frontline immuno-oncology (IO)
ADTRAN Misses Q2 Earnings Estimates Despite Higher Revenues
ADTRAN Holdings, Inc. ADTN reported mixed second-quarter 2025 results, with the top line surpassing the Zacks Consensus Estimate but the bottom line missing the same.The company recorded a top-line


